NCT01756508View on ClinicalTrials.gov

Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

September 1, 2012

Primary Completion Date

April 15, 2017

Study Completion Date

December 1, 2017

Conditions
End-Stage Renal DiseaseKidney FailureGraft Reperfusion Injury
Interventions
DRUG

eculizumab

Eculizumab 1200 mg/m2 will be administered once, 1 hour before graft reperfusion

Trial Locations (1)

119992

Russian Scientfic Center of Surgery, Moscow

All Listed Sponsors
lead

Russian Academy of Medical Sciences

OTHER

NCT01756508 - Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury | Biotech Hunter | Biotech Hunter